Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal Disease
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Data on the capacity of hemodialysis to remove dolutegravir (DTG) from plasma in patients
with end-stage renal disease (ESRD) on hemodialysis (HD) are lacking. If DTG was removed from
plasma by HD, it would be possible to have subtherapeutic drug concentrations at the end of
HD sessions.
Phase:
Phase 4
Details
Lead Sponsor:
Fundacio Lluita Contra la SIDA Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia